Barclays Upgrades Amylin Pharmaceuticals (AMLN) to Overweight
More News related to AMLN
- After-Hours Movers 1/27: NFLX, PFBC, ALGN, SOA, ESIO Higher; QCOM, EGHT, TTEK, LSI, SRDX, VRUS Lower
- Amylin (AMLN) Misses Street's Q4 Views
- Amylin Pharmaceuticals Reports 2009 Financial Results
- Skymark Research Initiates Independent Research Coverage on Amylin Pharmaceuticals, Inc.
- Trading Radar for 01/27: ConocoPhillips (COP), Boeing (BA), Abbott (ABT), General Dynamics (GD), E*TRADE (ETFC) Report
More News related to Trader Talk
- S&P Announces Change to US Index: TSRA for FIF
- Baidu (BIDU) is up about $35 or 8% following a blow-out Q4
- Morgan Stanley Says Buy Commodities on Recent Dip
- Germany is considering loan guarantees for Greece and other troubled euro partners - WSJ
- Sprint (S): Q4 Earnings Preview
Barclays upgrades Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) from Equal Weight to Overweight and raised their price target from $16 to $22.
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, focuses on improving the lives of people with diabetes, obesity, and other diseases through the discovery, development, and commercialization of innovative medicines.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Trader TalkUpgrades
Stocks Mentioned
+0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
